The 17 references in paper E. Zavialova S., A. Al-Shukri S., I. Korneev A., O. Yagmurov D., Е. Завьялова С., А. Аль-Шукри С., И. Корнеев А., О. Ягмуров Д. (2009) “РОЛЬ АНТИГЕНОВ Ki-67, р53 и bcl-2 В ПРОГНОЗИРОВАНИИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ ПЕРЕХОДНО-КЛЕТОЧНОГО РАКА МОЧЕВОГО ПУЗЫРЯ // THE ROLE OF Ki-67, p53 and bcl-2 ANTIGENS IN THE PROGNOSIS OF CLINICAL COURSE OF TRANSITIONAL CELLULAR CANCER OF THE URINARY BLADDER” / spz:neicon:nefr:y:2009:i:1:p:90-94

1
Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of major cancers in 1985. Int J Cancer 1993;54:594- 606
(check this in PDF content)
2
Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006;12:7369-7373
(check this in PDF content)
3
Lebret T, Becette V, Herve JM. Prognostic value of MIB- 1 antibody labeling index to predict response to Bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol 2000; 37:654-659
(check this in PDF content)
4
Pich A, Chiusa L, Formiconi A. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 2002;95:784-790
(check this in PDF content)
5
Santos L, Costa C, Pereira S, Koch M, Amaro T, Cardoso F, Guimaraes T, Bento MJ, Lobo F, Pinto S, Lopez C. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumor. Ann Oncol 2003;14(9):1419-1424
(check this in PDF content)
6
Quintero A, Alvarez-Kindelan J, Luque RJ. Ki-67 MIB1 labeling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;59:83-88
(check this in PDF content)
7
Zlotta AR, Noel JC, Fayt I, Drowart, Van Vooren JP, Huygen K, Simon J, Schulman CC. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 1999;161(3):792- 798
(check this in PDF content)
8
Hollstein M, Sidransky D, Volgelstein B, Harris CC. P53 mutations in human cancers. Science 1991;253:49
(check this in PDF content)
9
Lane DP Cancer. P53, guardian of the genome. Nature 1992;358:15
(check this in PDF content)
10
Kuczyk MA, Bokemeyer C, Serth J, Hervatin C, Oelke M, Hofner K, Tan HK, Jonas U. P53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995;31A(13-14):2243-2247
(check this in PDF content)
11
Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez- Carrero J, Nogueira-March JL. P53 and Ki-67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol 2002;41(2):182-8; discussion 188-189
(check this in PDF content)
12
Lipponen PK. Overexpression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 1993;53(3):365-370
(check this in PDF content)
13
Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T, Kawanishi M. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer 1996; 78(8):1762-1774
(check this in PDF content)
14
Lipponen PK, Aaltomaa S, Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumors. Histopathology 1996;28920:135-140
(check this in PDF content)
15
Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AA, Barterlink H, Verheij M. Prognostic factors in transitional cell cancer of the bladder: an emerging role for bcl-2 and p53. Radiother Oncol 2001;61(2):169-175
(check this in PDF content)
16
Atug F, Turkeri L, Ozyurek M, Akdas A. Bcl-2 and p53 overexpression as risk factors in transitional cell carcinoma of the bladder. Int Urol Nephrol 1998; 30(4):455-461
(check this in PDF content)
17
Bol MGW, Baak JPA, van Diermen B, Buhr-Wildhagen S, Janssen EAM, Kjellevold KH, Kruse AJ, Mestad O, Ogreid P. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks. J Clin
(check this in PDF content)